China’s Diagnosis and Treatment Guidelines for Primary Liver Cancer (2022), issued by the National Health Commission, recommends combining AFP-L3 and DCP to improve the diagnosis rate of early HCC. This evidence concerns the gene AFP and hepatocellular carcinoma.